Covalis Bets $30M on Core Scientific's AI Pivot Despite DeepValue's Cautious Stance on Risks

What happened

Covalis (Gibraltar) Ltd initiated a new $30.29 million position in Core Scientific by buying 2,080,550 shares in Q4 2025, betting on the company's transition from bitcoin mining to AI/HPC colocation. This aligns with Core Scientific's reported progress, including ~350 MW energized under the CoreWeave contract toward a ~590 MW target by early 2027, as highlighted in the DeepValue report. However, the report underscores significant unresolved risks, such as a material weakness in internal controls over conversion accounting that has triggered restatements and governance concerns. Additionally, Core Scientific faces a looming $500 million term loan maturity in Mar 2027, high capex commitments, and heavy customer concentration on CoreWeave, which could strain liquidity and execution. While the investor's move signals external confidence in the AI infrastructure story, it does not address the fundamental financial and operational vulnerabilities documented in recent SEC filings.

Implication

Investors should interpret this bet as a vote of confidence in Core Scientific's AI narrative, yet it does not mitigate the core challenges identified in the DeepValue report. The company must still prove it can consistently convert energized MW into billable colocation revenue while maintaining customer-funded capex to avoid balance-sheet strain. Moreover, remediation of the material weakness in internal controls and a clear refinancing plan for the Mar 2027 maturity are essential to reduce tail risks and restore credibility. Failure to address these issues could lead to liquidity crunches, forced dilution, or asset sales, outweighing any short-term sentiment boost from new investments. Therefore, while the news may attract speculative interest, prudent investors should await concrete evidence of execution improvements and risk reduction before considering a position.

Thesis delta

The DeepValue thesis of waiting for observable remediation of internal controls and refinancing progress remains unchanged, as this investor activity does not alter the underlying risk profile. The $30M bet reinforces the AI pivot narrative but provides no evidence of mitigated execution hurdles or financial stability. Consequently, no material shift in the investment call is justified, and the 'WAIT' rating persists until quarterly filings show tangible progress.